US-guided Sciatic Nerve Block: Evaluation of the Intraneural Ropivacaine Minimal Effective Volume (MEV90)

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, double-blinded study evaluates intraneural ropivacaine 1% Minimal Effective Volume (MEV90) for ultrasound-guided (US) popliteal sciatic nerve block, with Up-and-down methodology.

To evaluate any neurological complications, an electrophysiological assessment will also be performed preoperatively and at 5 weeks after surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ASST Gaetano Pini-CTO
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• Age above 18 years old

• ASA I-III

• Signed informed consensus

Exclusion Criteria:

• ASA IV

• Unstable neurological disease

• DM type I-II

• Allergy to ropivacaine-mepivacaine

• Opioid chronic treatment

• Consensus refusal or not valid

• Rheumatoid arthritis

• Baseline electrophysiological study positive finding

• Postoperative intensive care required